Literature DB >> 2147673

Uptake of clarithromycin by rat lung cells.

Y Kohno1, H Yoshida, T Suwa, T Suga.   

Abstract

To evaluate the affinity of clarithromycin (6-O-methylerythromycin A) for lung tissue, the in-vivo and in-vitro uptake of [14C]clarithromycin and [14C]erythromycin by rat lung cells was compared, and the characteristics of the uptake mechanism were investigated. After the administration into the external jugular vein of rats, clarithromycin was found in much higher concentrations in the lung tissue than erythromycin. In isolated lung cells, clarithromycin was also found in greater concentrations than erythromycin. The amount of clarithromycin was ten times that of erythromycin after 5 min incubation. This uptake profile was quite different from that observed in isolated liver cells. Uptake by lung cells for both antibiotics was shown to be an active process, as revealed by the need for cell viability, a suitable environmental temperature and ATP. Clarithromycin uptake proved to be dependent in part upon mitochondrial oxidative respiration. Kinetic analysis indicated that clarithromycin transport was saturable, with a relatively high binding affinity and velocity of uptake. Clarithromycin transport was significantly inhibited by 6-O-methylerythromycin analogues, but was not influenced by other analogues, including erythromycin. Competitive inhibition of clarithromycin uptake was demonstrated by 6,11,12.4"-tetra-O-methylerythromycin, one of the mutual inhibitors. These findings may suggest that clarithromycin utilizes a carrier-mediated transport system in the lung cells, which is common to 6-O-methylerythromycins. This difference of uptake mechanism between both antibiotics may account in part for the greater clarithromycin uptake by the lung cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147673     DOI: 10.1093/jac/26.4.503

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

Review 2.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 3.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 4.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

5.  Sustained distribution of aerosolized PEGylated liposomes in epithelial lining fluids on alveolar surfaces.

Authors:  Keita Kaneko; Kohei Togami; Eri Yamamoto; Shujun Wang; Kazuhiro Morimoto; Shirou Itagaki; Sumio Chono
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

6.  Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.

Authors:  F Kees; M Wellenhofer; H Grobecker
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.